2Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HLA-B27. Lancet, 1973, 1: 904-907.
3Khan MA, yen der Linden SM. A wider spectrum of spondyloarthropathies. Semin Arthritis Rheum. 1990, 20:107-113.
4Ven der Linden SM, Khan MA. The risk of ankylosing spondylitis in HLA-B27 positive individuals: a reappraisal. J Rheumatol, 1984, 11:727-728.
5Van den Elsen PJ, Gobin S J, van Eggermnnd MC, et al. Regulation of MHC class Ⅰ and Ⅱ gene transcription: differences and similarities. Immunogenetics, 1998, 48: 208-221.
6Johnson DR. Locus-specific constitutive and cytokine-indueed HLA class 1 gene expression. J Immunol, 2003, 170: 1894-1902.
7Van den Elsen PJ. Holling TM. Kuipers HF, et al. Transcriptional regulation of antigen presentation. Curr Opin Immunol, 2004, 16: 67-75.
8Dangorja NS, DeLay ML. Kingsbury DJ, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem, 2002, 277: 23459-23468.
9Tran TM, Satumtira N, Dorris ML, et al. HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and muhimers that bind to the chaperone BiP. J Immunol, 2004, 172:5110- 5119.
10Turner M J, Sowders DP, DeLay ML, et al. HLA-B27 misfolding in transgenic rats is assciated with activation of the unfolded protein response. J lmmunol. 2005, 175: 2438-2448.
